Notably, sodium–glucose cotransporter-2 (SGLT2) inhibitors, which have established pleiotropic effects, show particularly consistent effects: a recent network meta-analysis reported greater EAT reduction with SGLT2 inhibitors than with GLP-1RAs or structured exercise in individuals with type 2 diabetes and/or obesity, and a complementary meta-analysis linked SGLT2 therapy to lower EAT volume/thickness, providing a mechanistic bridge to observed benefits in heart-failure populations. The gene discussed is SLC5A2; the disease is obesity disorder.